Tanzhou Chen

Dr. Tanzhou Chen


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
RLRuoyang Lin
Ruoyang Lin
XLXianfan Lin
Xianfan Lin
JWJinming Wu
Jinming Wu
TCTanzhou Chen
Tanzhou Chen
ZHZhiming Huang
Zhiming Huang
Esophageal squamous cell carcinoma (ESCC) is one of the most frequently occurring diseases in the world. Rabdosia rubescens (RR) has been demonstrated to be effective against ESCC; however, the mechanism is unknown. The primary gene modules related to the clinical characteristics of ESCC were initially investigated in this research using weighted gene co-expression network analysis (WCGNA) and differential expression gene (DEG) analysis. We employed network pharmacology to study the hub genes linked with RR therapy on ESCC. A molecular docking simulation was achieved to identify the binding activity of central genes to RR compounds. Lastly, a chain of experimentations was used to verify the inhibitory effect of RR water extract on the ESCC cell line in vitro. The outcomes revealed that CCNA2, TOP2A, AURKA, CCNB2, CDK2, CHEK1, and other potential central targets were therapeutic targets for RR treatment of ESCC. In addition, these targets are over-represented in several cancer-related pathways, including the cell cycle signaling pathway and the p53 signaling pathway. The predicted targets displayed good bonding activity with the RR bioactive chemical according to a molecular docking simulation. In vitro experiments revealed that RR water extracts could inhibit ESCC cells, induce cell cycle arrest, inhibit cell proliferation, increase P53 expression, and decrease CCNA2, TOP2A, AURKA, CCNB2, CDK2, and CHEK1. In conclusion, our study reveals the molecular mechanism of RR therapy for ESCC, providing great potential for identifying effective compounds and biomarkers for ESCC therapy.

7 October 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
DXDan Xiang
Dan Xiang
JYJiaxin Yang
Jiaxin Yang
MXMiaofang Xiao
Miaofang Xiao
CLCong Long
Cong Long
YLYangxuan Lin
Yangxuan Lin
TCTanzhou Chen
Tanzhou Chen
Alternative splicing is a pivotal regulatory mechanism in cellular biology that critically influences the tumorigenesis, progression, and phenotypic diversity of cancer. This study aimed to assess the intricate details and regulatory mechanisms of alternative splicing in gastric cancer. We constructed a comprehensive map of aberrant alternative splicing events in gastric cancer through bioinformatic analysis of public databases and clinical samples. Our study identified many abnormal splicing events in gastric cancer tissues, with exon skipping being the most frequent event. SNRPB, a key spliceosome component and principal splicing factor, was associated with the aberrant splicing of numerous splicing factors and oncogenes, influencing the p53 signaling pathway in the development and progression of gastric cancer. SNRPB directly regulates the selective splicing of TP53 by modulating its downstream factor, PUF60, thus facilitating the initiation and progression of gastric cancer. Therefore, SNRPB overexpression is linked to poor prognosis in gastric cancer and is a potential biomarker and therapeutic target.

10 October 2023 in ChemRxiv
Verified
Preprint
Open access
PDF file
QWQinyang Wang
Qinyang Wang
XHXiaoqu Hu
Xiaoqu Hu
HYHao Yin
Hao Yin
TCTanzhou Chen
Tanzhou Chen
DXDanli Xie
Danli Xie
MLMingdong Lu
Mingdong Lu
Gasdermin protein, a membrane disruptor, can mediate immunogenic pyroptosis and elicit anti-tumour immune function. However, cancer cells downregulate gasdermin and develop membrane repair mechanisms to resist pyroptosis. Therefore, an artificial membrane disruptor (AMD) that can directly mediate membrane rupture in pyroptosis-deficient cells and induce antitumour immune responses in a controllable manner is valuable in preclinical and clinical research. Here, we have established a micron-scale Ce6-based artificial membrane disruptor (AMD) to directly induce plasma membrane rupture (PMR) in gasdermin-deficient tumour cells. Compared to free Ce6 molecules, micron-scale AMDs specifically localised Ce6 to the plasma membrane without labelling other organelles. Due to the plasma membrane specificity, AMDs mediated irreversible and fast PMR under 660 nm red light. In addition, our AMDs were able to mediate PMR and lytic cell death in a catalytic manner, such that the Ce6 used by AMDs is one-fifth that of Ce6 alone when mediating 80% of cancer cell death. In vivo, our AMDs exhibited tumour targeting and penetration, indicating that light-driven PMR was tumour specific. We applied AMDs to antitumour therapy in gasdermin-deficient tumours, the results showed that all tumours could be efficiently eliminated with negligible damage to major organs by synergising with anti-PD-1 therapy. Tumour regression was correlated with PMR-mediated inflammation and T-cell-based immune responses. Our study provides new insights for designing the bioinspired membrane disruptor for PMR and mediating anti-tumour immunotherapy. In addition, AMD is a reliable tool for investigating the immunogenicity of PMR in vitro and in vivo.

13 May 2026 in Cell Death & Disease
Verified
Journal Article
Open access
DXDan Xiang
Dan Xiang
JYJiaxin Yang
Jiaxin Yang
MXMiaofang Xiao
Miaofang Xiao
CLCong Long
Cong Long
YLYangxuan Lin
Yangxuan Lin
TCTanzhou Chen
Tanzhou Chen

1 June 2026 in Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
Verified
Journal Article
Closed access
HBHan Bu
Han Bu
XZXinyu Zhang
Xinyu Zhang
CJCiliang Jin
Ciliang Jin
ZCZhenghao Chen
Zhenghao Chen
RHRui Hu
Rui Hu
TCTanzhou Chen
Tanzhou Chen
Background and Aims: One of the key challenges in endoscopic submucosal dissection (ESD) is achieving effective intraoperative mucosal traction. Although numerous countertraction technologies have been developed, there is still room for optimization. This randomized controlled trial was designed to assess the comparative effectiveness of a novel robotic assistance system (FASTER) versus conventional ESD techniques for managing colorectal neoplasia. Methods: A total of 24 ESD procedures were performed on 6 different anatomic sites (rectum and sigmoid colon) of 4 pigs. Twelve procedures were performed with the FASTER-assisted method and 12 with the conventional method. Key efficacy outcomes consisted of total procedure time, submucosal dissection time, submucosal dissection speed, and direct visual dissection rate. Secondary outcomes evaluated the complete resection rate and perioperative adverse events. Results: Compared with the conventional ESD group (C-ESD), the total procedure time of the FASTER-assisted ESD group (F-ESD) was significantly lower (11.5 vs. 18.0 min; P <0.001). Compared with the conventional ESD, FASTER-assisted ESD significantly increased the submucosal dissection speed (0.7 vs. 0.4 cm 2 /min; P <0.001), shortened the submucosal dissection time (4.9 vs. 10.7 min; P <0.001), and improved the rate of direct vision dissection (99.0% vs. 83.2%; P <0.001). The operation difficulty score of the F-ESD group was significantly lower than that of the C-ESD group (1.0 vs. 3.0; P <0.001). FASTER-assisted ESD significantly optimized the primary outcome measures in the treatment of sigmoid and rectal lesions. Conclusions: The FASTER system reliably provided continuous visual feedback and dynamic tissue manipulation throughout the ESD procedure. In this prospective preclinical animal investigation, it significantly shortened operation time and reduced surgical adverse events, offering an innovative solution for optimizing ESD procedures in colorectal treatment.

24 July 2026 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
XLXinmiao Li
Xinmiao Li
FJFeng Jiang
Feng Jiang
BFBinbo Fang
Binbo Fang
LLLifan Lin
Lifan Lin
JZJianjian Zheng
Jianjian Zheng
TCTanzhou Chen
Tanzhou Chen
Introduction: Metabolic dysfunction‐associated fatty liver disease (MAFLD) is a common chronic liver condition marked by abnormal lipid metabolism. Objectives: Small nucleolar RNA host gene 5 (SNHG5) is involved in the regulation of cell proliferation and apoptosis and was previously identified as a profibrotic factor in liver fibrosis. However, its role in MAFLD remains unclear. This study aimed to elucidate the contribution of SNHG5 to MAFLD progression. Methods and results: SNHG5 expression was markedly elevated during MAFLD progression, whereas SNHG5 inhibition suppressed lipid accumulation. Transcriptomic sequencing of primary hepatocytes overexpressing SNHG5 demonstrated significant downregulation of monocarboxylate transporter 1 (MCT1), a key lactate transporter. Integrated lactyl‐proteomic and proteomic analyses further revealed that SNHG5 overexpression promoted lactylation of the non‐histone protein AT‐rich interaction domain 1A (Arid1a) at K391, thereby driving excessive lipid accumulation. Acyltransferase assays indicated that both P300 and HBO1 participated in SNHG5‐mediated Arid1a lactylation. In vivo, hepatocyte‐specific SNHG5 knockout markedly attenuated hepatic lipid accumulation and MAFLD progression, whereas simultaneous hepatocyte‐specific deletion of SNHG5 and MCT1 restored lipid accumulation compared with SNHG5‐deficient mice. Conclusion: SNHG5 promotes lipid accumulation and MAFLD progression through induction of MCT1‐mediated Arid1a K391 lactylation.